Rispoval Pasteurella
Rispoval Pasteurella
Authorised
- Mannheimia haemolytica, serotype A1, strain NL 1009, capsular antigen
- Mannheimia haemolytica, serotype A1, strain NL 1009, leucotoxoid
Product identification
Medicine name:
Rispoval Pasteurella
Active substance:
- Mannheimia haemolytica, serotype A1, strain NL 1009, capsular antigen
- Mannheimia haemolytica, serotype A1, strain NL 1009, leucotoxoid
Target species:
-
Cattle (calf)
Route of administration:
-
Intramuscular use
Product details
Active substance and strength:
-
Mannheimia haemolytica, serotype A1, strain NL 1009, capsular antigen345.00/relative unit(s)1.00Dose
-
Mannheimia haemolytica, serotype A1, strain NL 1009, leucotoxoid200.00/relative unit(s)1.00Dose
Pharmaceutical form:
-
Lyophilisate for solution for injection
Withdrawal period by route of administration:
-
Intramuscular use
- Cattle (calf)
-
Meat and offal0day
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI02AB04
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Portugal
Package description:
- Available only in Portuguese
- Available only in Portuguese
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Portugal Lda.
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium
Responsible authority:
- DGAV
Authorisation number:
- N724/03 DGV
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 19/06/2023
How useful was this page?:
